SNBTS provide end to end solutions for Advanced Therapies, we offer a full range of consultancy, development, translation, CMC (chemistry, manufacture and control) and GMP-manufacturing services that can be tailored to your requirements. We have over 20 years’ experience delivering autologous and allogeneic products for in vivo studies and First in Human, Phase 1 and Phase 2 trials.
As a NHS establishment we are uniquely positioned to support academic and other early-stage developers in the translation of their ‘proof of concept’ stage products into GMP-compatible processes, and to manufacture these products for early-stage clinical trials.
We have proven expertise working with somatic cells, pluripotent stem cells and their derivatives, and genetically modified cell therapies. Alongside our GMP capability we have extensive in-house Quality Control capacity specifically developed for Advanced Therapy Medicinal Products (ATMPs), including endotoxin and sterility, cell identity and function, and stability studies.
